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Hydrolysis of glucosylceramides by the enzyme glucosylceramide-b-glucosidase (GlcCer’ase) results in ceramide,
a critical component of the intercellular lamellae that mediates the epidermal permeability barrier. A disturbance of
ceramide formation is supposed to inﬂuence the transepidermal water loss in common skin diseases like atopic
eczema or psoriasis. The aim of this study was to investigate whether GlcCer’ase levels were altered in the skin of
subjects with psoriasis vulgaris. Skin punch biopsies were taken from lesional and non-lesional psoriatic skin and
GlcCer’ase was evaluated both at the RNA and at the protein level. Normal skin from surgical patients provided the
baseline GlcCer’ase expression in healthy subjects. Our results show that GlcCer’ase mRNA expression was
decreased in psoriatic non-lesional skin compared to normal controls in all cases. Interestingly, in lesional psoriatic
skin the level of GlcCer’ase was increased compared to non-lesional skin in all cases. For the immunohistochem-
ical analysis, we used a newly synthesized monoclonal antibody anti-human GBC (GlcCer’ase-GST fusion protein).
The results conﬁrmed that GlcCer’ase, mainly present in the upper epidermis, was decreased in psoriatic skin
compared to normal control and was increased in lesional compared to non-lesional psoriatic skin. Our ﬁndings
support the concept that alteration in water permeability barrier in lesional psoriatic skin can serve as a trigger for
the upregulation of the expression of enzymes like GlcCer’ase with consequent stimulation of ceramide generation.
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The epidermal permeability to water and to water soluble
material is mediated by a system of lamellar sheets of lipids
localized in the intercellular space of the stratum corneum
(SC) as described best by the ‘‘brick and mortar’’ model
(Elias, 1983). These lamellar sheets, enriched with ceram-
ides (Cer),1 cholesterol and free fatty acids, serve as a bar-
rier against excess transepidermal water loss (TEWL), (Elias,
1983; Lampe et al, 1983a; Grubauer et al, 1989b). Especially
Cer have shown to have a distinctive role in epidermal per-
meability barrier homeostasis (Holleran et al, 1991). SC Cer
comprise an heterogeneous family of at least eight struc-
tural groups that differ from each other in the architecture of
the polar sphingoid head group, in the length of the non-
polar fatty acid chains and a-hydroxylation of constituent
amide-linked fatty acid (Wertz et al, 1985; Vietzke et al,
2001; Ponec et al, 2003). Cer[EOS] and Cer[EOH] containing
linoleic acid o-esterified to N-acyl fatty acids are key con-
stituents of the extracellular lamellar membrane organiza-
tion. In addition to this layer, easily removed by organic
solvents, a portion of the o-hydroxyacids pool forms a
monolayer covalently bound to the cornified envelope,
which can be analyzed after exhaustive extraction of free
epidermal lipids and release through mild alkaline hydrolysis
(Wertz et al, 1989; Behne et al, 2000). The resulting corn-
eocyte lipid envelope is thought to serve as a scaffold upon
which extracellular lamellar bilayer structures form in the
SC, being of great relevance for epidermal barrier function
(Downing, 1992).
In addition to a de novo sphingolipid synthesis, catalyzed
by the enzyme serine palmitoyltransferase (Holleran et al,
1991), there are two main pathways for Cer generation. One
is represented by the degradation of GlcCers, catalyzed by
glucosylceramide-b-glucosidase (GlcCer’ase), and the oth-
er by the hydrolysis of sphingomyelin (SM) catalyzed by
sphingomyelinase (SMase). Both the early activation of
SMase and the later degradation of GlcCers are essential
for skin barrier repair (Holleran et al, 1993, 1994a; Jensen
Abbreviations: AE, atopic eczema; Cer, ceramides; GBC, Glc-
Cer’ase-GST fusion protein; GlcCer, glucosylceramide; GlcCer’ase,
glucosylceramide-b-glucosidase; SC, stratum corneum; TEWL,
transepidermal water loss
1The following Cer code used (Motta et al, 1993; Robson et al,
1994) contains: Cer EOS (or Cer 1): ester-linked fatty acids (E), o-
hydroxy fatty acids (O), and sphingosines (S). Cer NS (or Cer 2):
nonhydroxy fatty acids (N) and sphingosines (S). Cer NP (or Cer 3):
non-hydroxy fatty acids (N) and phytosphingosines (P). Cer EOH
(or Cer 4): ester-linked fatty acids (E), o-hydroxy fatty acids (O), and
6-hydroxy sphingosines (H). Cer AS (or Cer 5): a–hydroxy fatty
acids (A) and sphingosines (S). Cer AP (or Cer 6): a–hydroxy fatty
acids (A) and phytosphingosines (P). Cer AH (or Cer 7): a–hydroxy
fatty acids (A) and hydroxy sphingosines (H).
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et al, 1999). Epidermal sphingomyelins have been shown to
be important precursors of Cer[NS] and Cer[AS], but other
Cer species, including the o-hydroxy fatty acid-containing
Cer do not derive from sphingomyelins, but rather from
GlcCers (Uchida et al, 2000; Hamanaka et al, 2002).
GlcCer’ase enzyme activity has been described in the up-
permost differentiated epidermal layers and accounts for
the hydrolysis of acylGlcCers and GlcCers and the accu-
mulation of Cer in the SC (Lampe et al, 1983b; Holleran et al,
1992; Takagi et al, 1999). The degradation of protein-bound
GlcCer, the precursor of protein-bound Cer, by GlcCer’ase
requires the presence of a cofactor, saposin C, and also of
negatively charged lysosomal lipids (Doering et al, 1999).
Deficiency of GlcCer’ase as genetically determined in
Gaucher’s disease (or induced in the Gaucher mouse mod-
el) or inibition of its activity in the epidermis decreases the
amount of SC Cers and creates an incompetent epidermal
permeability barrier function (Holleran et al, 1993, 1994b;
Doering et al, 1999), demonstrating the importance of the
hydrolysis of GlcCer in skin barrier homeostasis. A signif-
icant increase in GlcCer’ase was demonstrated following
skin barrier disruption and increased TEWL in hairless mice;
furthermore, the addition of a GlcCer’ase inhibitor delayed
permeability barrier recovery (Holleran et al, 1994a).
Alteration of Cer composition, including epidermal pro-
tein-bound Cer, has been reported in several skin diseases
characterized by an abnormal SC and water permeability
barrier function, like atopic eczema (AE) and psoriasis
(Wertz et al, 1989; Melnik, 1991; Motta et al, 1993, 1994b;
Bleck et al, 1999; Macheleidt et al, 2002).
There is evidence, that an abnormal expression of en-
zymes or cofactors involved in Cer biosynthesis or degra-
dation may play a role in both AE and psoriasis (Murata
et al, 1996; Cui et al, 1997; Alessandrini et al, 2001). In our
previous study evaluating prosaposin (the precursor of the
mature saposins, key cofactors for sphingolipid and glyco-
sphingolipid degradation) and SMase levels in lesional and
non-lesional skin of psoriatic patients, we found decreased
levels of prosaposin in both lesional and non-lesional skin
and of SMase in lesional skin of patients with psoriasis vul-
garis (Alessandrini et al, 2001). In order to ascertain whether
the alteration of skin barrier function seen in psoriatic dis-
ease could be also related to disturbances in the Glc-
Cer’ase pathway of Cer generation, we asked whether
the expression of GlcCer’ase would be compromised in the
skin of patients with psoriasis vulgaris. We quantified the
RT-PCR products and evaluated the protein expression of
GlcCer’ase in normal skin and in lesional and non-lesional
psoriatic epidermis.
Results
The mRNA expression of GlcCer’ase is decreased in
psoriatic epidermis; its level is higher in lesional com-
pared with non-lesional psoriatic skin The separation
of the GlcCer’ase and Glyceraldehyde 3-phosphate de-
hydrogenase (GAPDH) RT-PCR products by gel elect-
rophoresis and ethidium bromide staining showed a de-
crease in the mRNA expression of GlcCer’ase in psoriatic
epidermis compared with normal control skin (Fig 1) as
shown also by the semi-quantitative assessment of the
GlcCer’ase PCR bands normalized to GAPDH (Fig 2). Al-
though interindividual differences in GlcCer’ase mRNA ex-
pression were observed, the level of GlcCer’ase mRNA
expression in psoriatic lesional skin was higher compared
with non-lesional skin in all cases (Figs 1 and 2). Fur-
thermore, the elevation of the mean GlcCer’ase mRNA
Figure1
Gelelectrophoresis of GlcCer’ase RT-PCR products. Gel-
electrophoresis of GlcCer’ase (GlcCer, upper lanes) and GAPDH (low-
er lanes) in representative normal epidermis (NS), and in five psoriatic
subjects (P1–P5), non-lesional skin left (a), lesional skin right (b). Total
cellular RNA was isolated from epidermal specimen (NS, P1–P5). RT-
PCR was performed with GlcCer’ase and GAPDH primer, and sepa-
rated by gel electrophoresis on a 2% agarose gel stained with ethidium
bromide as described (see Materials and Methods).
Figure2
Semiquantitative analysis of GlcCer’ase PCR bands and statistics.
Relative density levels of GlcCer’ase PCR bands are expressed in per-
centage of GAPDH. The graph in (a) shows control levels in a repre-
sentative sample of normal skin (NS) and the levels in non-lesional (left)
and lesional (right) skin of five psoriatic subjects (P1–P5). The densito-
metric values are obtained from the corresponding ethidiumbromide-
stained PCR reaction products presented in Fig 1. The box plot in (b)
shows the mean, SE and SD of the values in non-lesional (NL) and
lesional (L) skin of psoriatic subjects (n¼5), po0.05.
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expression in lesional compared with non-lesional psoriatic
skin was statistically significant (Fig 2b; po0.05).
Three samples obtained by simply scraping off scales
from psoriatic lesions resulted in non-significant PCR bands
(data not shown).
Western immunoblotting The separation of aliquots of
human Cerezyme protein and purified GlcCer’ase-GST fu-
sion protein by SDS-PAGE and binding to the monoclonal
antibody GlcCer’ase-GST fusion protein (GBC)-1A5 (rat
IgM, k) showed one band at 58 kDa for human Cerezyme
and one band at 61 kDa for the GlcCer’ase-GST fusion
protein (Fig 3). The results were reproducible.
The protein level of GlcCer’ase is decreased in psoriatic
skin and higher in psoriatic lesional versus non-lesional
skin All samples investigated showed a very similar pattern
of immunoreactivity. In control skin, GlcCer’ase protein was
localized in the outer layers of human epidermis, the upper
stratum granulosum, and SC (Fig 4a). In non-lesional psoria-
tic epidermis GlcCer’ase immunoreactivity was lower com-
pared with control and localized only in few spots in the
transition zone between granular layer and SC (Fig 4c). In
lesional psoriatic epidermis GlcCer’ase immunoreactivity
was increased compared to non-lesional, both in the higher
stratum granulosum and in the lower SC (Fig 4d). The neg-
ative control showed no staining (Fig 4b) and the positive
control always showed a typical stain for cytokeratin (data
not shown).
Discussion
The results of this study show decreased levels of
GlcCer’ase in the skin of subjects with psoriasis vulgaris
compared with normal controls. Interestingly, lesional
psoriatic skin showed an increased level of GlcCer’ase
compared with non-lesional in all cases, both at the RNA
and at the protein level.
For the immunohistochemical study a newly synthesized
monoclonal antibody anti-human GBC was used. Its bind-
ing capacity was confirmed by western Immunoblotting
and by immunohistochemistry. The results obtained by
immunohistochemistry on normal control skin were in fact
comparable to previous studies on the localization of
GlcCer’ase activity and protein expression in human and
mouse skin (Holleran et al, 1992; Takagi et al, 1999). In order
to exclude the influence of the parakeratosis of the psoriatic
SC in our analysis, we evaluated samples obtained by
scraping off psoriatic lesions. We obtained no significant
GAPDH and GlcCer’ase PCR bands, demonstrating that
parakeratotic nuclei do not contain sufficient RNA to
Figure 3
Western Immunoblotting of human monoclonal anti-GBC antibody.
Aliquots of human Cerezyme (1) and GBC purified protein (2) were
separated by SDS-PAGE, blotted with monoclonal anti-GBC antibody
and developed (see Materials and Methods).
Figure 4
Immunohistochemical localization of
GlcCer’ase is showing in normal control
skin (a), in non-lesional (c) and lesional (d)
skin of psoriatic subjects and non-specific
primary negative control (b). The series in
(c) and (d) represents one individual. The
immunohistochemical analysis was per-
formed using the ABC method (see Ma-
terials and Methods). GlcCer’ase protein
in normal control skin was localized in
the granular–corneocyte transition zone
and in the stratum corneum (a, arrows). In
psoriatic non-lesional skin (c) GlcCer’ase
immunolocalization was decreased com-
pared to control and was present as spot-
ty reaction in the granular–corneocyte
transition zone (arrow). In psoriatic lesio-
nal skin (d) GlcCer’ase was increased
compared with (c) in the upper stratum
granulosum and in the lower stratum
corneum (arrows). No staining was de-
tected using a non-specific primary anti-
body (b). Scale bar¼30 mm.
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influence the results. This is in accordance with the finding
of solely condensed DNA and RNA in the parakeratotic cells
in psoriasis, presumably without metabolic function (Suzuki
et al, 1980).
Ceramide concentration in the epidermis depends on the
rate of de novo Cer synthesis (Holleran et al, 1991) as well
as on the availability of enzymes involved in Cer generation
from pre-existing precursors (Holleran et al, 1993, 1994a;
Jensen et al, 1999). Important signals for the upregulation of
skin lipid enzymes occur upon permeability barrier require-
ments (Grubauer et al, 1989a; Holleran et al, 1994a; Harris
et al, 1997; Stachowitz et al, 2002). Inhibition of sphingolipid
synthesis produces a delay in barrier recovery in response
to epidermal irritants, confirming the role of sphingolipids
for the maintenance of the epidermal permeability barrier
to water and water-soluble material (Grubauer et al, 1989a;
Holleran et al, 1991).
Abnormal skin lipid profiles can be associated with de-
ficient barrier function in common skin diseases like atopic
eczema and psoriasis, both of which exhibit hyperprolifer-
ation, impaired epidermal differentiation, and barrier function
(Melnik et al, 1991; Motta et al, 1994b). Most of the barrier
lipids are unbound and thus free extractable with organic
solvents (Vietzke et al, 2001). The human epidermis contains
also covalently bound Cer and fatty acids, which are of crit-
ical importance in the formation of the corneocyte lipid en-
velope (Wertz et al, 1989). The alteration in covalently bound
lipids was analyzed in lesional and non-lesional skin of AE
subjects. The authors found a significant reduction in pro-
tein-bound o-OH-Cer in both lesional and non-lesional ep-
idermis, compared with healthy controls, accompanied by
an increase of protein-bound o-OH-FA (Macheleidt et al,
2002). Also psoriatic scales showed to differ from normal SC
with augmented level of bound linoleic acid and alterations
in the covalently bound lipids (Wertz et al, 1989). A detailed
analysis of Cer composition of psoriatic scales revealed
decreased linoleic acid-esterified Cer (Cer[EOS]), and
Cer-containing phytosphingosine (Cer[NP] and Cer[AP]) com-
pared with normal control skin, and increased Cer contain-
ing sphingosine (Cer[NS] and Cer[AS]), (Motta et al, 1993,
1994a). The authors speculated that the relative decrease in
phytosphingosine-containing Cer and increase in sphingo-
sine-containing Cer in the psoriatic scale could derive from
deranged water bioavailability, caused by the excess water
loss occurring in psoriatic scales, compared to normal SC.
The decrease in Cer[EOS], which seems to have a critical
function in the molecular arrangement of the SC lamellar
lipid bilayer formation and assembly (Bouwstra et al, 1998),
can cause alterations in the molecular organization of the
SC in psoriasis (Motta et al, 1993; Ghadially et al, 1996).
Studies on patients with psoriasis vulgaris showed that
TEWL and water content in non-lesional skin were very
similar to normal control skin and only water retention ca-
pacity differed slightly from control (Berardesca et al, 1990).
On the other hand, the increase in TEWL in lesional psoriatic
epidermis has been well documented (Tagami and Yos-
hikuni, 1985; Serup and Blichmann, 1987). Also hydration
by bound water in the psoriatic lesions appears to be in-
ferior to control skin (Takenouchi et al, 1986). An ultrastruc-
tural analysis of the SC of psoriatic lesions has revealed
extremely narrow intercellular spaces between a large
number of parakeratotic corneocytes containing few path-
ological epidermal lipids lamellae (Fartasch, 1997).
An abnormal expression of enzymes or cofactors in-
volved in Cer biosynthesis or degradation may play a role
both in AE and in psoriasis (Murata et al, 1996; Cui et al,
1997; Alessandrini et al, 2001). According to two aforemen-
tioned studies, the level of prosaposin, the precursor of
mature saposins, was decreased in both atopic and in
psoriatic skin. Prosaposin-deficient mice, which lack the
activator protein for GlcCer’ase, accumulate GlcCer in the
SC and present abnormal lamellar lipid bilayers and thick-
ened stratum lucidum with evidence of scaling (Doering
et al, 1999). Also in the Gaucher mouse and in the
GlcCer’ase inhibitor-treated models, the skin samples show
abnormal lipid bilayers in the epidermis with loosely packed,
unprocessed lamellar body-derived sheets, similarly to the
Type II Gaucher neonate characterized by very low levels of
GlcCer’ase (Holleran et al, 1994b). On the other hand, the
importance of sphingomyelinase-dependent Cer production
has been demonstrated both in a mouse model as well as in
patients with Niemann–Pick disease following acute barrier
disruption (Jensen et al, 1999; Schmuth et al, 2000). There-
fore, for the recovery of barrier function following acute
disruption and in skin diseases with disturbed water barrier,
e.g., atopic eczema or psoriasis, both pathways of Cer
generation may be required. Nevertheless, it was shown
that Cer[EOS] are only produced by GlcCer’ase and not
by sphingomyelinase (Uchida et al, 2000), therefore the
pathway of Cer generation by GlcCer’ase seems critical.
Galactocerebrosides appear to be potent stimulators
of GlcCer’ase activity in the epidermis (Hara et al, 1998).
A recent work performed by the same group showed that
topical application of a compound, which mimics b-gala-
ctosylceramide and increases GlcCer’ase activity in kera-
tinocytes, significantly reduced the TEWL, improving skin
barrier function, in a UVB-induced barrier disruption mouse
model (Fukunaga et al, 2003).
GlcCer’ase activity in atopic and aged dry skin was
evaluated by analyzing SC sheets obtained by tape strip-
ping. The authors found no difference in GlcCer’ase activity
between non-lesional atopic epidermis/aged dry skin and
control (Jin et al, 1994). We did not measure the enzyme
activity, but we observed a clear decrease of GlcCer’ase
mRNA and protein level in the skin of psoriatic subjects
compared with normal controls. The decrease of GlcCer’-
ase affects the postsecretory processing of GlcCer to Cer.
Considering the studies performed by Berardesca et al
(1990), this decrease should have no affect on the water
retention capacity in psoriatic non-lesional skin. Interest-
ingly, we observed an increase in GlcCer’ase level in
lesional psoriatic epidermis compared to non-lesional. This
increase suggests a compensatory capacity of psoriatic
lesional skin to try and generate Cer in response, e.g., to
water barrier requirements. It was shown that the epidermis
of active plaque psoriasis generates a large number of la-
mellar bodies, which remain in the corneocyte cytosol and
do not form functional intercellular bilayer structures (Ghadi-
ally et al, 1996). We can then speculate that the unbalanced
generation of Cer species with different molecular structure
and physical properties can affect the coherence of the SC
in psoriasis patients.
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Apart from the importance of Cer as structural compo-
nent of SC lipids, there is an additional aspect in Cer func-
tion that should be taken into account. The balance of Cer/
GlcCer appears to be critical for maintaining cellular home-
ostasis. Although Cer are involved in the regulation of ker-
atinocyte proliferation and differentiation (Geilen et al, 1997),
GlcCer accumulation by inhibition of GlcCer’ase stimulates
epidermal proliferation in hairless mouse epidermis, result-
ing in epidermal hyperplasia (Marsh et al, 1995). Epidermal
hyperplasia has been shown to be related to permeability
barrier dysfunction (Proksch et al, 1993), which in turn has
been suggested to induce the recruitment of inflammatory
cells in the epidermis and contribute to the inflammatory
status of this disorder (Nickoloff and Naidu, 1994). Altera-
tions in the balance of GlcCer/Cer and permeability barrier
requirements in psoriasis could therefore affect keratinocyte
proliferation, SC desquamation and inflammation, all as-
pects being relevant in the pathogenesis of psoriasis.
Materials and Methods
Subjects and materials Fresh skin tissue biopsies were obtained
from the lesional and non-lesional skin of five male subjects with
psoriasis vulgaris (age ranging from 25 to 39 y). Two additional
biopsies from the lesional skin of two psoriatic subjects were used
for immunohistochemical analysis. The study was conducted ac-
cording to the Declaration of Helsinki Principles. The ethical com-
mittee of the Technical University of Munich approved the study,
and volunteers were enrolled in the study after providing written
informed consent. Normal control skin (n¼ 5) was obtained from
non-lesional areas of surgical tumor resections from non-inflam-
matory skin diseases (basalioma, keratoma). All specimens under-
went a histopathological examination after routine hematoxylin &
eosin (H&E) staining, which revealed that all samples were typical
examples of ‘‘active plaque’’ type psoriasis.
All chemicals were purchased from Sigma-Aldrich Chemie (De-
isenhofen, Germany), unless otherwise specified.
Isolation of mRNA The mRNA was isolated from the specimens
obtained from both lesional and non-lesional areas of five male
subjects with psoriasis vulgaris and from three normal control
subjects. Three additional samples were obtained from the same
psoriatic subjects by simply scraping off the psoriatic lesions. RNA
isolation was performed as previously described (Alessandrini et al,
2001).
Desoxyribonuclease (DNAse) digestion To avoid DNA contam-
ination, the mRNA was digested with 10U DNAse (Roche Diag-
nostics GmbH) with the addition of 10 U RNAse Inhibitor (Roche
Diagnostics GmbH, Petersberg, Germany) followed by phenol/
chloroform extraction and ethanol precipitation.
RT-PCR Reverse transcription was performed as previously de-
scribed (Alessandrini et al, 2001). For each experiment, primer
concentrations, RNA amounts, and PCR cycles were titrated to
establish standard conditions. The validity of quantitative compar-
isons of PCR products was insured by using a number of PCR
cycles mapped to, within the linear curve. For PCR, 1–3 mL of the
sample was incubated in 20 mM Tris-HCl, pH 8.4, 50 mM KCl, 1.5
mM MgCl2, 200 mM dNTP mix, and 0.2 pmol of GlcCer’ase and
GAPDH primers (see below). The thermal profile used on a Hybaid
Limited TouchDown Thermal Cycler (Hybaid, Middlesex, UK) con-
sisted on denaturation at 941C for 45 s, annealing at 541C for 30 s
and an extension temperature of 721C for 1 min for 29 cycles. By
optimized conditions, the PCR runs were repeated on the same
RNA samples to assure the reproducibility of the data.
Oligonucleotides used for PCR The oligonucleotides used were
chosen overlapping introns, to avoid the amplification of genomic
DNA. GAPDH was used as internal control. GlcCer’ase (forward
primer: 50-ATGGCTCTGCTGTTGTGGTC-30; reverse primer: 50-GCA-
CACAGCGCATGTTCAC-30), (GenBank, accession no. D-13286), and
GAPDH (forward primer: 50-GGTGAAGGTCGGAGTCAACGGA-30, re-
verse primer: 50-GAGGGATCTCGCTCCTGGAAGA-30), (GenBank,
accession no. M33197).
Quantiﬁcation of RT-PCR—products and statistics PCR reac-
tions were separated by gel electrophoresis on 2% agarose gels
stained with 0.4 mg per mL ethidiumbromide. The gels were vis-
ualized over an on-line UV light source transilluminator (Gel Doc
1000 Video documentation System, Bio-Rad, Hercules, California).
The PCR products of the expected size (392 bp for GlcCer’ase,
and 430 bp for GAPDH) were then manually defined and the bands
intensity was quantified using Quantity One quantitation software
(Bio-Rad). The intensity of the PCR bands of GlcCer’ase were ex-
pressed normalized to GAPDH. For statistical analysis, a t test was
used to compare GlcCer’ase mRNA expression (in % of GAPDH) of
psoriatic non-lesional to lesional skin. A p value below 0.05 was
considered to be significant.
Cloning of recombinant GlcCer’ase protein DNA coding for hu-
man GlcCer’ase (nucleotides 721–1422 of the human GlcCer’ase
coding sequence, GenBank, accession no. D-13286) was ampli-
fied from human skin cDNA by PCR (forward primer: 50-AT-
ATGAATTCGGCGCCGGTGGAGACATCTACCACCAGACCTGG-30;
reverse primer: 50-TATCTCGAGCTAATGATGGTGATGGTGATGGC-
CCTGGCGACGCCACAGGTA-30). The PCR products were cloned
into the EcoRI/XhoI sites of pGEXDBamHI (Leenders et al, 1996), a
modified pGEX-2T vector (Amersham Biosciences) for the bacterial
expression of GST-fusion protein (GBC).
GBC protein expression and puriﬁcation The recombinant
plasmid was transformed into Escherichia coli BL21 DE3 codon
plus RIL (Stratagene). After bacteria were grown at 371C to an
OD600 of approximately 0.8 in LB medium supplied with ampicillin
(50 mg per mL), protein expression was induced by addition of
IPTG (0.25 mM final). Bacteria were harvested after overnight in-
duction by centrifugation, resuspended in PBS and lysed by four
freeze–thaw cycles in the presence of lysozyme. After centrifuga-
tion for 15 min at 17,500  g at 41C the supernatants were again
centrifuged for 20 min at the same conditions. GST-fusion protein
was bound from the supernatant to GT-sepharose (Pharmacia) and
eluted by Tris HCl/glutathione after several washing steps as de-
scribed (Leenders et al, 1996). The eluates were directly used for
generation of antibodies, or SDS-PAGE.
Production of monoclonal antibodies against the C-term of
GBC Lou/C rats were immunized subcutaneously and intraperi-
toneally with a mixture of GBC-GST fusion protein (50 mg), 5 nmol
CPG oligonucleotide (ODN 2006, TIB Molbiol, Berlin, Germany),
500 mL PBS and 500 mL IFA. After a 4-wk interval a final boost
without adjuvant was given 3 d before fusion of the rat spleen cells
with the murine myeloma cell line P3X63-Ag8.653 (Kremmer et al,
1995). Hybridoma supernatants were tested in an ELISA using bac-
terial extracts from E. coli expressing either the GBC fusion protein
or an irrelevant GST fusion protein. Monoclonal antibodies reacting
with GlcCer’ase-GST fusion protein and not with an irrelevant GST
fusion protein were analyzed by western immunoblotting.
Western immunoblotting For western immunoblotting both pu-
rified GlcCer’ase-GST fusion protein (GBC, 6 mg) and human
Cerezyme protein (4 mg) were used. Cerezyme is a recombinant
form of human GlcCer’ase used for medical purposes (e.g.: to re-
place GlcCer’ase in Gaucher disease patients) and was generously
donated by Dr Paul (Genzyme Therapeutics, England). Aliquots
of the two proteins were separated by SDS-PAGE (8% total
acrylamide concentration). Molecular weight standards were from
Bio-Rad (Munich, Germany). Proteins were transferred from gels to
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PVDF membranes (Pall) by semi-dry blotting (Trans-Blot SD Semi-
Dry Transfer Cell; Bio-Rad) according to the manufactor’s protocol.
Non-specific binding of primary antibodies was reduced by pre-
incubating the membranes after blotting with 5% skimmed milk
powder in PBS for 30 min. A solution of monoclonal anti-GBC
antibody 1:1000 in PBS/5% skimmed milk powder was incubated
overnight at 41C. After washing, the membranes were incubated
for 2 h at room temperature with a peroxidase-labeled goat anti-
rat IgGþ IgM (Hþ L) secondary antibody (1:1000 in PBS/0.5%
skimmed milk powder, Dianova). Peroxidase was detected using
the ECL system (Amersham Biosciences, UK). By optimized con-
ditions, the western Immunoblots were repeated to assure the re-
producibility of the data.
Immunohistochemistry For the immunohistochemical study, all
biopsies taken from lesional and non-lesional skin of three psoriatic
subjects (see above, subjects and materials), two additional biop-
sies from lesional skin of psoriatic subjects and normal control skin
(n¼ 5) were snap frozen in liquid nitrogen for cryostat sectioning.
Frozen tissue samples were submerged in Optimum Cutting Tem-
perature embedding compound (OCT, Tissue-Tek, Miles Labora-
tory, Elkhart, Indiana) and cryostat sections (4 mm) were prepared
on positively charged slides and allowed to air-dry. Tissue fixation
was obtained with fresh 2% paraformaldehyde in phosphate-buff-
ered saline (PBS), for 5 min, and methanol, for 10 min at 41C. The
tissue sections were further processed for indirect immunohisto-
chemistry with an ABC-based method (Vector Laboratories, Burlin-
game, California) previously described (Alessandrini et al, 2001).
Briefly, after blocking both endogenous biotin and peroxidases, the
sections were incubated overnight at 41C either with a monoclonal
specific antibody anti-GBC (GBC-1A5, dilution factor 1:50, see
Results, Western Immunoblotting), or a non-specific purified rat
isotype control (Vector Laboratories) or a monoclonal anti-cyto-
keratin PAN antibody (10 mg per mL; BM, Mannheim, Germany)
used respectively as negative and positive controls. Specific bind-
ing was detected using a biotin-conjugated horse secondary anti-
rat affinity-purified antibody, avidin–biotin peroxidase complex
(Vector Laboratories), and a substrate solution containing H2O2
and diaminobenzidine. The slides were then counterstained with
hematoxylin, dehydrated, mounted. and coverslipped.
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